RecruitingNot Applicable

Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Longitudinal Monitoring MRD Based on ctDNA

China255 participantsStarted 2023-11-20

Plain-language summary

This study will conduct a prospective cohort study to verify the predictive value of ctDNA-MRD longitudinal monitoring model in predicting postoperative recurrence, verify whether ctDNA-MRD longitudinal monitoring model can indicate recurrence earlier than imaging examination, and explore the feasibility of guiding adjuvant therapy after curative treatment based on this model.

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Male or female patients aged 18-75 years;
✓. Preoperative imaging examination diagnosed hepatocellular carcinoma (BCLC) stage 0 / stage A/stage B, eligible for radical surgery;
✓. ECOG physical status score is 0-1;
✓. Child-Pugh score is 5-6 points (Level A);
✓. Not received any anti-tumor therapy;
✓. Laboratory tests were at normal levels within 7 days before enrollment.

Exclusion criteria

✕. Patient can't provide blood samples for ctDNA testing;
✕. Patient with two or more types of tumors at the same time;
✕. Non-primary liver lesions;
✕. Pregnant or lactating women;
✕. Patient with a history of other malignant tumors within the past 5 years or at the same time, except cured skin basal cell carcinoma, cervical carcinoma in situ and thyroid papillary carcinoma;
✕. Patient with serious heart disease;
✕. Other conditions deemed unsuitable for inclusion by the researcher.

What they're measuring

2-year recurrence-free survival rate

Timeframe: 2 years

Trial details

NCT IDNCT06157060

SponsorZhujiang Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-11-20

Contact for this trial

Mingxin Pan, Prof.

+8618928918216 pmxwxy@sohu.com

View on ClinicalTrials.gov More Hepatocellular Carcinoma Resectable trials